Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT Phase 3b trial
J Am Acad Dermatol 2023;89:486–95. doi: 10.1016/j.jaad.2023.04.063
High levels of clinical responses were seen throughout the first 48 weeks with bimekizumab treatment. These were maintained to Week 96 in patients with moderate-to-severe plaque PsO.
Patients switching from secukinumab to bimekizumab at Week 48 also saw improved clinical responses at Week 96, similar to patients who received 96 weeks of continuous bimekizumab.
